Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Pisano, Marina ^a   Pagnan, Gabriella ^b   Dettori, Maria A ^a   Cossu, Sara ^a   Caffa, Irene ^b   Sassu, Ilaria ^a   Emionite, Laura ^c   Fabbri, Davide ^a   Cilli, Michele ^c   Pastorino, Fabio ^b   Palmieri, Giuseppe ^a   Delogu, Giovanna ^a   Ponzoni, Mirco ^b   Rozzo, Carla ^a  

^a CNR   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' DIMETHOXY 3,3' DIHYDROXY 5,5' DIFORMYL 1,1' BIPHENYL; 2,2'3,3' TETRAMETHOXY 5,5' DIFORMYL 1,1' BIPHENYL; 4,4' [5,5'6,6' TETRAMETHOXY (1,1' BIPHENYL) 3,3' DIYL]BIS(BUT 3 EN 2 ONE); BIPHENYL DERIVATIVE; CASPASE; CURCUMIN; CYTOCHROME C; KETONE DERIVATIVE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROECTODERM TUMOR; NICK END LABELING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SECRETION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECT; FEMALE; HUMAN; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; FEMALE; HUMANS; IN SITU NICK-END LABELING; MELANOMA; MICE; MICE, NUDE; NEUROBLASTOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 77952962215     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-137     Document Type: Article

References (39)

1. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BMJ 2005, 331:698. 10.1136/bmj.331.7518.698, 1226263, 16179724.
2. Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol 2007, 157:338-343. 10.1111/j.1365-2133.2007.08029.x, 17596175.
3. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006, 81:500-507. 10.4065/81.4.500, 16610570.
4. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009, 107:46-57. 10.1002/jcb.22094, 19277986.
5. Muller S, Matthay KK. Neuroblastoma: biology and staging. Current Oncology Reports 2009, 11:431-438. 10.1007/s11912-009-0059-6, 19840520.
6. Oberthuer A, Theissen J, Westermann F, Hero B, Fisher M. Molecular characterization and classification of neuroblastoma. Future Oncology 2009, 5:625-639. 10.2217/fon.09.41, 19519203.
7. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann NY Acad Sci 2005, 1056:206-217. 10.1196/annals.1352.010, 16387689.
8. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005, 41:1955-1968. 10.1016/j.ejca.2005.05.009, 16081279.
9. Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007, 31:243-305. 10.1016/j.currproblcancer.2007.04.001, 17645940.
10. Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal BB. Curcumin and cancer: An "old-age" disease with an "alge-old" solution. Cancer Lett 2008, 267:133-64. 10.1016/j.canlet.2008.03.025, 18462866.
11. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23:363-98.
12. Marìn YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH. Curcumin downregulates the constitutive activity of NF-kB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007, 17:274-283. 10.1097/CMR.0b013e3282ed3d0e, 17885582.
13. Bush JA, Cheung KJ, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001, 271:305-14. 10.1006/excr.2001.5381, 11716543.
14. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, Rozzo C. Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 2007, 6:8. 10.1186/1476-4598-6-8, 1785384, 17233906.
15. Formelli F, Cleris L. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant subline. Eur J Cancer 2000, 36:2411-9. 10.1016/S0959-8049(00)00335-X, 11094318.
16. Quitschke WW. Differential solubility of curcuminoids in serum and albumin solutions: implications for analytical and therapeutic applications. BMC Biotechnol 2008, 8:84. 10.1186/1472-6750-8-84, 2612664, 18990234.
17. Delomenede M, Bedos-Belval F, Duran H, Vindis C, Balta M, Negre-Salvayre A. Development of Novel Antiatherogenic Biaryls: Design, Synthesis, and Reactivity. J Med Chem 2008, 51:3171-3181. 10.1021/jm7014793, 18465848.
18. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98:1142-57. 10.1093/jnci/djj309, 16912267.
19. Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res 2009, 15:1199-209. 10.1158/1078-0432.CCR-08-2477, 19228726.
20. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989, 182:16-19. 10.1016/0003-2697(89)90710-0, 2604040.
21. Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005, 24:6785-6795. 10.1038/sj.onc.1208829, 16007159.
22. Keshelava N, Tsao-Wei D, Reynolds CP. Pyrazoloacridine is active in multidrugresistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res 2003, 9:3492-3502.
23. Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 2008, 126:85-94. 10.1016/j.jconrel.2007.11.010, 18166243.
24. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008, 14:7320-9. 10.1158/1078-0432.CCR-08-0804, 19010847.
25. Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M. Ligand targeted liposomal therapies of neuroblastoma. Curr Med Chem 2007, 14:3070-8. 10.2174/092986707782793916, 18220743.
26. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-6. 10.1126/science.281.5381.1312, 9721091.
27. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998, 281:1309-12. 10.1126/science.281.5381.1309, 9721092.
28. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 2009, 284:34553-60. 10.1074/jbc.M109.040139, 19854829.
29. Karunagaran D, Rashmi R, Kumar TR. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets 2005, 5:117-29. 10.2174/1568009053202081, 15810876.
30. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001, 7:1894-900.
31. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991, 57:1-7. 10.1055/s-2006-960004, 2062949.
32. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005, 5:231-7. 10.1038/nrc1560, 15738985.
33. Boyer MJ, Tannock IF. Cellular and molecular basis of chemotherapy. The Basic Science of Oncology 1998, 350-369. New York: McGraw-Hill, Tannock IF, Hill RP.
34. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24:1199-208. 10.1093/carcin/bgg082, 12807727.
35. Chih-Li L, Jen-Kun L. Curcumin: a Potential Cancer Chemopreventive Agent through Suppressing NF-kB Signaling. J Cancer Mol 2008, 4:11-16.
36. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancers. Oncogene 1999, 18:6938-6947. 10.1038/sj.onc.1203221, 10602468.
37. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kB transcription factors. Oncogene 1999, 18:6910-6924. 10.1038/sj.onc.1203238, 10602466.
38. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009, 15:425-430. 10.1158/1078-0432.CCR-08-0149, 19147746.
39. Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X, Yang S. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 2009, 17:2623-2631. 10.1016/j.bmc.2008.10.044, 19243951.